Antibody-mediated Rejection in Kidney Transplant

Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection
NCT05452317 | Observational

This study investigates the burden of disease among kidney transplant recipients that have developed Chronic Active Antibody Mediated Rejection (caAMR) compared with kidney transplant recipients that have not developed caAMR

Trial Information
3 Sites
50 Participants
Recruiting
18 Years

If interested, contact clinicaltrials@cslbehring.com for more information

SUBMIT
Keck Medical Center of USC
Los Angeles,California,United States,90033
University of Maryland School of Medicine, Div. of Nephrology
Baltimore,Maryland,United States,21201
The Washington University
Saint Louis,Missouri,United States,63130

Study Eligibility Criteria

  • Chronic Active AMR group:
  • 18 Years and older
  • Recipient of blood group system (ABO) compatible solitary kidney transplant between [1Jan2013] and [1Jan2018]
  • Chronic active AMR diagnosed via kidney biopsy based upon Banff criteria. Patients who additionally have diagnoses such as TCMR, acute tubular necrosis, recurrence of primary kidney disease are also eligible if not the predominant pathology.
  • DSA antibodies within prior 6 months of the biopsy which confirmed chronic active AMR
  • Minimum of 3 years of follow up data following diagnosis of chronic active AMR (unless patient had died)
  • eGFR at time of diagnosis of chronic active AMR of >25ml/min/1.73m2
  • Non-Chronic active AMR group:
  • Age 18 years or older
  • Recipient of ABO compatible solitary kidney transplant between [1 Jan 2013] and [1Jan2018]
  • No documented diagnosis of chronic active AMR during the data extraction period. Patients with other diagnoses such as TCMR, acute tubular necrosis, recurrence of primary kidney disease are also eligible. Patients may or may not have had biopsies.
  • Minimum of 4 years of follow up data since transplant (unless patient has died)
  • eGFR of >25ml/min/1.73m2 at time of matching
  • Chronic active AMR group:
  • Recipient of a multi-organ transplant
  • ABO-incompatible transplant
  • Patient lost to follow up within the first 3 years post-diagnosis of chronic active AMR and whose allograft status (graft failure or patient death) is unknown.
  • Non-Chronic active AMR group:
  • Recipient of a multi-organ transplant
  • ABO-incompatible transplant
  • Patient lost to follow up within the first 4 years of transplant and whose allograft status (graft failure or patient death) is unknown.

Additional Studies

Additional studies can be found at ClinicalTrials.gov